SlideShare ist ein Scribd-Unternehmen logo
1 von 118
BLEEDING DISORDERS
Check out ppt download link in description
Or
Download link : https://userupload.net/wxvqfbo7ywqu
CONTENTS…
Introduction
History
- A Royal Disease
Finding the cause
Identifying clotting factors
Hemostasis
Bleeding disorders
-Vascular disorders
-Coagulation disorders
-Platelet disorders
Dental Evaluation
Dental management
Conclusions
References
Introduction
History
• In the Talmud, 2nd
century AD
•A 12th century Arab physician named Albucasis
•In the U.S., the transmission of hemophilia from mothers
to sons was first described in the early 1800s.
•In 1803, a Philadelphia physician named Dr. John Conrad
Otto wrote an account of "a hemorrhagic disposition
existing in certain families."
• The word "Hemophilia" first appeared in a description of a
bleeding disorder condition at the University of Zurich in
1828.
CLICK HERE TO DOWNLOAD
THIS PPT
https://userupload.net/wxvqfbo7ywqu
A Royal Disease
Finding the Cause
 In the 20th century doctors looked for the cause of
excessive bleeding. Until then, they had believed
that the blood vessels of hemophiliacs were simply
more fragile.
 1925
Although it is probably the most common hereditary
bleeding disorder (affecting approximately 1% to 2%
of the population), von Willebrand disease was not
recognized until 1925.
 1937,
Patek and Taylor, two doctors at Harvard,
They called it "anti-hemophilic globulin."
 1944
Pavlosky, a doctor from Buenos Aires,
Argentina, did a lab test which showed that
blood from one hemophilic patient could
correct the clotting problem in a second and
vice-versa.
Identifying Clotting Factors
 In the 1960s the clotting factors were identified
and named.
 An article in Nature in 1964
 In the 1950s and early 1960s, hemophilia and
other bleeding problems were treated with whole
blood or fresh plasma. Unfortunately, there
wasn't enough of the factor VIII or IX proteins in
these blood products to stop serious internal
bleeding.
 Then, in the 1960s, cryoprecipitate was
discovered by Dr. Judith Pool
CLICK HERE TO DOWNLOAD
THIS PPT
https://userupload.net/wxvqfbo7ywqu
 Then, later in the 1960s and early 1970s,
concentrates containing factor VIII and IX
began to be available. (freeze-dried
powdered concentrates)
 blood products carried blood-borne viruses
like hepatitis C and HIV.
 In the 1990s, modern treatment, using safer
factor concentrates, has again improved the
outlook
Recent progress includes:
• New clotting factor products and drugs such as desmopressin
acetate also known as DDAVP,
• New, synthetic (not derived from plasma) clotting products
that take advantage of recombinant technologies
• Better screening methods to detect and remove viruses and
other agents from factor concentrates and blood products
• Improved surgical options
• Advanced genetic testing methods
• Medically supervised home-infusion therapy
• Prophylactic treatment
HEMOSTASIS
 Platelets
 Coagulation factors
Platelets-origin
Life span : 7-14 days
Site of destruction: Spleen
Normal count : 1.5 - 4.5 lacks / cc
Increase in count : Thrombocytosis
Decrease in count : Thrombocytopenia
Decrease in platelet count below 40,000is associated with hemorrhagic disorders.
CLICK HERE TO DOWNLOAD
THIS PPT
https://userupload.net/wxvqfbo7ywqu
a. Physiological Variations :
 Seasonal - Count is more during winter season.
 Pregnancy - Count decrease
 Exercise, excitement, injection of adrenaline, high altitude
- Increased count.
b. Pathological Variations :
 Increased platelet count seen after splenectomy idiopathic.
 Decreased platelet count is seen in
 Viral infection
 Aplastic anaemia
 Idiopathic
HEMOSTASIS
 Primary Hemostasis
 Blood vessel contraction
 Platelet Plug Formation
 Secondary Hemostasis
 Activation of Clotting Cascade
 Deposition & Stabilization of Fibrin
 Tertiary Hemostasis
 Dissolution of Fibrin Clot
 Dependent on Plasminogen Activation
Detailed Events of Coagulation
Figure 17.13b
Coagulation
Figure 17.13a
Bleeding Disorders: Causes, Types, and Diagnosis
Bleeding Disorders: Causes, Types, and Diagnosis
Tests of Hemostasis:
 Screening tests:
 Bleeding.T - 10m. Platelet & BV function
 Prothrombin.T – Extrinsic, aPTT – Instrinsic
 Thrombin.T – common path. (DIC)
 Specific tests:
 Factor assays – hemophilia.
 Tests of thrombosis – TT,
 Platelet function studies:
Adhesion, Aggregation, Release tests.
 Bone Marrow study
Disorders of Hemostasis
Classification :
• Disorders of Blood vessels
• Scurvy, senile purpura, Henoch-Schonlein syndrome.
• Disorders of Platelets
• Thrombocytopenia ITP, TTP, HUS, DIC.
• Aspirin therapy, Thrombasthenia,
• Disorders of Coagulation
• Extrinsic, intrinsic, combined.
• Other disorders
• Post transfusion purpura.
Vascular disorders:
Petechiae, purpura, ecchymoses
senile purpura
vitamin C deficiency (scurvy)
Connective tissue disorders
Infections – Meningococcus
Henoch-Schonlein Purpura-Immu
Platelet Coagulation
Petechiae, Purpura Hematoma, Joint bl.
Senile PurpuraSenile Purpura
Petechiae inPetechiae in
VasculitisVasculitis
(Rocky Mountain Spotted Fever)(Rocky Mountain Spotted Fever)
Henoch-Schonlein purpura
 Immune disorder
 Children
 Follows infection
 Petechiae with
edema and
itching.
Henoch-Schonlein purpura
20y Male, fever, painful symmetric polyarthritis for a day. During the next two days,
edema and palpable purpura developed.
Disorders of coagulation
 Hemophilia A(Factor VIII Deficiency)
 What Is It?
The incidence of hemophilia A is one in 10,000
live male births. About 17,000 Americans have
hemophilia.
Inheritance Pattern
 Hemophilia A is caused
by an inherited sex-
linked recessive trait with
the defective gene
located on the X
chromosome.
Bleeding Disorders: Causes, Types, and Diagnosis
Genetic counseling may be
advised for carriers.
 Female carriers can be identified by testing.
 A woman is definitely a hemophilia carrier if she is:
• the biological daughter of a man with hemophilia;
• the biological mother of more than one son with hemophilia;
• the biological mother of one hemophilic son who has at least
one other blood relative with hemophilia.
A woman may or may not be a hemophilia carrier if she is:
• the biological mother of one son with hemophilia;
• the sister of a male with hemophilia;
• an aunt, cousin or niece of an affected male related through
maternal ties;
• the biological grandmother of one grandson with hemophilia.
Symptoms & Diagnosis
 Bruising
 Spontaneous bleeding
 Bleeding into joints and associated pain and
swelling
 Gastrointestinal tract and urinary tract hemorrhage
 Blood in the urine or stool
 Prolonged bleeding from cuts, tooth extraction, and
surgery
 People whose clotting activity is 5 percent of normal
may have only mild hemophilia.
Bleeding Disorders: Causes, Types, and Diagnosis
Treatments
 In the past, mild hemophilia A was typically
treated with infusion of cryoprecipitate or
desmopressin acetate (DDAVP),
 . Today, experts recommend desmopressin
injection or Stimate nasal spray.
 cryoprecipitate
 Depending on the severity of the disease, DDAVP
or factor VIII concentrate -prior to dental extractions
and surgery to prevent bleeding.
 Immunization with hepatitis B vaccine.
 Gene therapy and fetal tissue implant techniques
 People who have hemophilia should also avoid
certain drugs that can aggravate bleeding problems:
 Aspirin
 Heparin
 Warfarin
 Certain analgesics such as nonsteroidal anti-
inflammatory drugs
 MASAC made recommendations for treatment of
hemophilia in November of 1999.
They include:
1. Factor VIII products for patients who are HIV
seronegative, including Recombinant factor VIII,
2. Immunoaffinity purified factor VIII concentrates
3. Cryoprecipitate is not recommended because of the
risk of HIV and hepatitis infection.
4. Mild hemophilia A should be treated with
desmopressin, in a DDAVP injection or Stimate
nasal spray.
complications
 Chronic joint deformities
 Intracerebral hemorrhage
Hemophilia B
(Factor IX Deficiency)
 . Hemophilia B ("Christmas disease" )
 Is a deficiency in clotting factor IX.
 Hemophilia A is seven times more common
than hemophilia B.
 The incidence of hemophilia B is one in
34,500 men.
 Inheritance Pattern
 Hemophilia B is caused
by an inherited sex-
linked recessive trait
with the defective gene
located on the X
chromosome. Females
are carriers of this trait.
Genetic counseling may be advised for carriers. Female carriers can be
identified by testing.
A woman is definitely a hemophilia carrier if she is:
 the biological daughter of a man with hemophilia;
 the biological mother of more than one son with hemophilia; • the
 biological mother of one son with hemophilia and has at least one
other
 blood relative with hemophilia.
A woman may or may not be a hemophilia carrier if she is:
 the biological mother of one son with hemophilia;
 the sister of a male with hemophilia;
 an aunt, cousin or niece of an affected male related through maternal
ties;
 the biological grandmother of one grandson with hemophilia.
Symptoms include:
 nosebleeds
 bruising
 spontaneous bleeding
 bleeding into joints and associated pain and
swelling
 gastrointestinal tract and urinary tract hemorrhage
 blood in the urine or stool
 prolonged bleeding from cuts, tooth extraction and
surgery
 prolonged bleeding following circumcision
 People whose clotting activity is 5% of normal may
have only mild hemophilia.
DIAGNOSIS:
 A doctor may suspect hemophilia in a child
whose bleeding is unusual.
 A laboratory analysis of blood samples
 Determine the severity by testing the activity
of factor IX.
Treatments
• Infusing the missing clotting factor.
• To prevent a bleeding crisis- taught to administer
factor IX concentrates at home at the first signs of
bleeding.
• Factor IX concentrate may be given prior to dental
extractions and surgery to prevent bleeding.
• Milder forms of hemophilia need to have dental or
other surgery, the drug desmopressin acetate
(DDAVP) may be given to improve clotting temporarily
so that transfusions can be avoided.
MASAC made recommendations for treatment of
hemophilia B in
November of 1999. They include
• Recombinant factor IX products for patients who are HIV
seronegative,
• Patients who are HIV-seropositive should also be treated
with high purity products such as immunoaffinity purified
and recombinant factor VIII products.
• For patients with inhibitors to factors VIII and IX, there is
Recombinant Factor VIIa (NovoSeven). Produced by baby
hamster kidney cells, no human albumin or other proteins
are used in its production, reducing virus risk.
There is also Porcine factor VIII (Hyate C) and activated
prothrombin complex concentrates
Complications
• Chronic joint deformities,
• Intracerebral hemorrhage
may also occur.
• Thrombosis may occur
following use of factor IX
concentrate.
 Von Willebrand Disease
 What Is It?
 von Willebrand disease is a hereditary
deficiency or abnormality of the von
Willebrand factor in the blood, a protein that
affects platelet function
Bleeding Disorders: Causes, Types, and Diagnosis
 Researchers have identified many variations of the
disease, but most fall into the following classifications
• Type I: This is the most common and mildest form of von
Willebrand disease. Levels of von Willebrand factor are
lower than normal, and levels of factor VIII may also be
reduced.
• Type II: In these people, the von Willebrand factor itself
has an abnormality. Depending on the abnormality, they
may be classified as having Type IIa or Type IIb.
In Type IIa, the level of von Willebrand factor is
reduced, as is the ability of platelets to clump together.
In Type IIb, although the factor itself is defective, the
ability of platelets to clump together is actually increased.
 Type III: This is severe von Willebrand
disease. These people may have a total
absence of von Willebrand factor, and factor
VIII levels are often less than 10%.
 Pseudo (or platelet-type) von Willebrand
disease: This disorder resembles Type IIb von
Willebrand disease, but the defects appears to
be in the platelets, rather than the von
Willebrand factor.
 Inheritance Pattern
Like hemophilia, the disease is passed down through the
genes. occurs in men and women equally.
Types I and II are usually inherited in what is known as a
"dominant" pattern.
Type III von Willebrand disease, however, is usually
inherited in a "recessive" pattern.
 Symptoms and Diagnosis
 A parent with a history of bleeding problems.
 Typically, a child bruises easily or has bleeds
excessively after a skin cut, tooth extraction,
tonsillectomy or other surgery.
 A woman may have increased menstrual
bleeding. Bleeding may worsen at times.
 On the other hand, hormonal changes, stress,
pregnancy, inflammation and infections may
stimulate the body to increase production of the
von Willebrand factor and temporarily improve
clot formation.
Diagnostic signs can include:
 normal platelet count
 prolonged bleeding time
 reduced von Willebrand factor level
 reduced platelet adhesion may occur
 reduced or increased platelet aggregation
(platelet aggregation test)
 ristocetin cofactor is reduced
MASAC made recommendations for treatment
of von Willebrand disease in November of
1999. They include:
• Stimate, desmopressin acetate.
(DDAVP),nasal spray or injection
• Viral-inactivated factor VIII preparations rich in
von Willebrand factor, such as Alphanate,
Humate-P and Koate DVI, are
recommended.
• Cryoprecipitate is not recommended except in
life-threatening emergencies because of the
risk of HIV and hepatitis infection.
 Complications
After any kind of surgery, hemorrhaging may occur.
The condition is worsened by the use of aspirin and
other nonsteroidal anti-inflammatory drugs.
Women may have heavy menstrual periods as well
as risks during pregnancy and childbirth. .
 Factor I Deficiency (Afibrinogenemia)
 What Is It?
 Fibrinogen, also known as factor I, is needed
for most types of platelet aggregation. It's the
last step in the clotting process—the "glue"
that holds the clot together.
 Included under factor I deficiency are several
rare coagulation disorders known as
congenital fibrinogen defects. They include:
• afibrinogenemia
• hypofibrinogenemia
• dysfibrinogenemia
 Inheritance Pattern
 The disorder is not sex-linked
 It affects both males and females with equal
frequency.
 It is autosomal recessive.
 Symptoms and Diagnosis
Few people who have any of these
disorders suffer symptoms, although some are
predisposed to form blood clots (thrombosis).
 Treatments
-Many people with hypofibrinogenemia or
dysfibrinogenemia need no treatment.
-Those who require treatment may be given
cryoprecipitate or fresh frozen plasma.
The goal of treatment is to raise the patient's
fibrinogen level to 100 mg/dL for minor bleeding
and up to 200 mg/dL for surgery or severe
bleeding. (One unit of fresh frozen plasma has
about 450 mg of fibrinogen.)
 Complications
-Risk of thrombosis.
-In women, menstrual bleeding can be a
severe problem and must be controlled
Factor II Deficiency(Prothrombin)
 What Is It?
 Prothrombin is a vitamin K-dependent
proenzyme that functions in coagulation.
1)a congenital version called
hypoprothrombinemia,
2)acquired version called
dysprothrombinemia.
 congenital, factor II deficiency is extremely
rare.
 Acquired factor II deficiency is more common.
It results from vitamin K deficiency, severe
liver disease and therapeutic use of
anticoagulant drugs.
 Inheritance Pattern
 A congenital factor II deficiency is a very rare
inherited disorder that results in deficient
blood clotting. The disorder is not sex-linked
as is hemophilia.
 It affects both males and females with equal
frequency.
 It is autosomal recessive,
Symptoms include:
• umbilical cord bleeding at birth
• nose bleeds
• abnormal menstrual bleeding
• abnormal bleeding after delivery
• bleeding after trauma
• bleeding after surgery
• easy bruising
Signs and Tests:
• prolonged prothrombin time
• prolonged partial thromboplastin time
• factor II assay showing decreased activity
• levels of prothrombin ranging from 2% to 50% of normal
Treatments
MASAC made recommendations for treatment of
factor II deficiency in November of 1999.
They include:
• Prothrombin complex concentrates (PCCs) can be
used, but these products vary considerably in the
amount of factors they contain.
• Fresh frozen plasma can be used as along as it is
processed to reduce the risk of viral infection.
 Complications
Bleeding has to be
controlled in instances
of trauma or surgery, or
else bleeding into the
brain or skull can occur.
 Factor V Deficiency (Para hemophilia)
What Is It?
 Factor V deficiency is also known as Owren's
disease or parahemophilia.
 This deficit was identified in Norway in 1943. Since
then about 150 cases have been reported, occurring
in both men and women. The exact frequency of this
rare disorder is unknown, but is estimated to be one
per 1 million
 Inheritance Pattern
 The disorder is not sex-linked as is hemophilia.
 It affects both males and females with equal
frequency.
 It is autosomal recessive,
 Several families with combined deficiencies of factors
V and VIII have been reported.
Symptoms and Diagnosis
Symptoms include:
 bleeding into the skin
 excessive bruising with minor injuries
 nose bleeds
 bleeding of the gums
 excessive menstrual bleeding
 prolonged or excessive loss of blood with surgery or
trauma
Diagnosing the deficiency involves tests and signs such
as:
 factor V assay showing decreased activity
 slightly prolonged bleeding time (in some people)
 prolonged partial thromboplastin time
 prolonged prothrombin time
Treatments
-There are no commercially available
concentrates of factor V, so fresh plasma or
fresh frozen plasma infusions are used .
-The half-life of factor V is 24 hours.
-This is an inherited disorder; there is no known
prevention.
 Complications
-Dangerous hemorrhaging can occur if bleeding
isn't controlled quickly.
- If platelets are used as a source of factor V,
antiplatelet antibodies can be induced.
 Factor VII Deficiency (Proconvertin or
Stable Factor)
 What Is It?
 This extremely rare disorder can be inherited
or acquired by people who do not have
hemophilia who take Coumadin, a drug used
to inhibit blood clotting.
 This disorder occurs in one in 500,000 males
and females.
 Congenital factor VII deficiency should be
distinguished from acquired factor VII
deficiency, which may result from liver
disease, vitamin K deficiency or other
malabsorption conditions.
 Inheritance Pattern
 The disorder is not sex-linked as is hemophilia.
 It affects both males and females with equal
frequency.
 It is also autosomal recessive,
 Those who have inherited a defective factor VII
gene from only one parent will usually have only
moderate levels of the factor but no symptoms.
Symptoms and Diagnosis
Symptoms include:
• bleeding of mucous membranes
• spontaneous nosebleeds
• excessive bruising
• prolonged menstrual bleeding
• bleeding into muscles
• bleeding into joints
Diagnosis is made by testing for factor VII in
the blood.
• Signs and tests include:
-prolonged prothrombin time
-- normal partial thromboplastin time
-- decreased factor VII assay
MASAC made recommendations for treatment of Factor VII
deficiency in November of 1999. They include:
• Recombinant factor VIIa (NovoSeven).
• Prothrombin complex concentrates (PCCs) can be
used, but these products vary considerably in the
amount of factors they contain.
• Fresh frozen plasma can be used as along as it is
processed to reduce the risk of viral infection.
TREATMENTS
Complications
These can include hemorrhages, strokes or
other neurological problems related to central
nervous system bleeding.
• Fatal intracranial bleeding caused by birth
trauma has occurred.
• Menstrual bleeding may also be severe.
THROMBOCYTOPENIA
 Definition
 Thrombocytopenia is any disorder in which
there are not enough platelets. Platelets are
cells in the blood that help blood to clot. This
condition is sometimes associated with
abnormal bleeding.
 Causes, incidence, and risk factors
Thrombocytopenia is often divided into three
major causes of low platelets:
1) Low production of platelets in the bone
marrow
2) Increased breakdown of platelets in the
bloodstream (called intravascular)
3) Increased breakdown of platelets in the
spleen or liver (called extravascular
1)Disorders that involve low production in the
bone marrow include:
-Aplastic anemia
-Cancer in the bone marrow
-Infections in the bone marrow (rare)
-Drugs (very rare)
2)Disorders that involve the breakdown of platelets
include:
 Immune thrombocytopenic purpura (ITP)
 Drug-induced immune thrombocytopenia
 Drug-induced nonimmune thrombocytopenia
 Thrombotic thrombocytopenic purpura
 Primary thrombocythemia
 Disseminated intravascular coagulation (DIC)
 Hypersplenism (an enlarged spleen)
 Symptoms
-Bruising
-Nose bleeds or bleeding in the mouth
` -Rash (pinpoint red spots)
-Other symptoms may be present as well,
depending on the cause of the condition. Mild
thrombocytopenia can occur without symptoms.
 Signs and tests
-CBC shows low platelets
-Bone marrow aspiration or Biopsy may be
normal or may show low megakaryocytes
(platelet precursors) or an infiltrating disease.
-PTTclotting study is normal
-PTclotting study is normal
-Platelet associated antibodies may be present
 Treatment
Treatment depends on the cause of the condition.
In some cases, a transfusion of platelets may be
required to stop or prevent bleeding.
Expectations (prognosis)
The outcome depends on the disorder causing the
low platelet counts.
Complications
- Hemorrhage
-Gastro intestinal blleding
-Bleeding in the brain (intracranial hemorrhage)
DISSEMINATED INTRAVASCULAR
COAGULATION
 DIC is a syndrome arising as a complication of many
different serious and life-threatening illnesses.
1) Acute (overt) form it is a hemorrhagic disorder,
2) Chronic (nonovert) DIC, on the other hand, is more
subtle and involves thromboembolism accompanied by
evidence of activation of the coagulation system.
Pathogenesis of DIC
Table 1. Conditions underlying DIC
syndrome
 Infections
Acute DIC: Bacteria and their toxins, fungi, viruses, rickettsiae
Chronic DIC: Any chronic infection (eg, tuberculosis, abscesses,
osteomyelitis)
 Noninfectious inflammatory diseases
Inflammatory bowel disease: Crohn's disease and similar
disorders
 Obstetrical complications
Acute DIC: Abruptio placentae, abortions (especially therapeutic
abortions), amniotic fluid embolism, hemorrhagic shock
Chronic DIC: Dead fetus syndrome
 Malignancy
Acute DIC: Acute promyelocytic leukemia, acute myelomonocytic
or monocytic leukemia, disseminated prostatic carcinoma
Chronic DIC: Lung, breast, gastrointestinal malignancy
 Vascular disease
Acute DIC: Brain infarction or hemorrhage
Chronic DIC: Aortic aneurysm, giant hemangioma
 Venoms
Acute DIC: Snake, spider (rare)

Trauma ;
 Acute DIC: Massive tissue destruction, brain damage
 Others
Acute DIC: Heparin-induced thrombocytopenia with thrombosis
(HITT), purpura fulminans in newborns (homozygous protein C
deficiency)zDIC, disseminated intravascular coagulation.
Clinical and laboratory findings in DIC
 Acute DIC
Clinical findings
 Multiple bleeding sites
 Ecchymoses of skin, mucous membranes
 Visceral hemorrhage
 Ischemic tissue
Laboratory abnormalities
 Coagulation abnormalities:
 prolonged prothrombin time,
 activated partial thromboplastin time,
 thrombin time; decreased fibrinogen levels;
increased levels of FDP (eg, on testing for
FDP, D dimer)
 Platelet count decreased as a rule but may be
falling from a higher level yet still be normal
 Schistocytes on peripheral smear
Clinical and laboratory findings in DIC
 Chronic DIC
Clinical findings
 Signs of deep venous or arterial thrombosis or embolism
 Superficial venous thrombosis, especially without varicose
veins
 Multiple thrombotic sites at the same time
 Serial thrombotic episodes
Laboratory abnormalities
 Modestly increased prothrombin time in some patients
 Shortened or lengthened partial thromboplastin time
 Normal thrombin time in most patients
 High, normal, or low fibrinogen level
 High, normal, or low platelet count
 Increased levels of FDP (eg, on testing for FDP, D dimer)
 Evidence of molecular markers* (eg, thrombin-antithrombin
complexes, activation markers on platelet membranes,
prothrombin fragment F1+2)
Treatment options for DIC syndrome
 . Treat the underlying disease
Avoid delay
Treat vigorously (eg, shock, sepsis, obstetrical problems)
 Manage the DIC
Acute DIC
Without bleeding or evidence of ischemia
No treatment
With bleeding
Blood components as needed
Fresh frozen plasma
Cryoprecipitate
Platelet transfusions
With ischemia
Anticoagulants (see "with thromboembolism" below) after
bleeding risk is corrected with blood products
Chronic DIC
 Without thromboembolism
No specific therapy needed but prophylactic drugs
(eg, low-dose heparin, low-molecular-weight heparin)
 With thromboembolism
Heparin or low-molecular-weight heparin, trial of warfarin
sodium (Coumadin).
 *Some patients respond to warfarin, others do not. Use of
low-molecular-weight heparin for prolonged periods has
potential hazards and is expensive but can be useful when
warfarin therapy fails despite good control (international
normalized ratio [INR], 2-3).
 IDIOPATHIC THROMBOCYTOPENIC
PURPURA
 What is ITP?
 What causes ITP?
 Who gets ITP?
 How does ITP affect children?
 How is ITP diagnosed?
 How is ITP treated in children?
 How does ITP affect adults?
 How is ITP treated in adults?
 What about ITP in pregnant women?
 Diagnosing ITP during pregnancy can be difficult,
because platelet counts may be low for other reasons.
About 5% of women have mildly low platelet counts at
the end of a normal pregnancy. The cause of this is
unknown. The platelet count goes back to normal right
after delivery.
 A baby born to a mother with ITP may have a low blood
platelet count a few days to a few weeks after birth.
These babies are usually kept in the hospital for several
days for observation (watching to make sure they are ok)
before they go can home.
 Thrombotic thrombocytopenic purpura
What is thrombotic thrombocytopenic purpura?
 Thrombotic thrombocytopenic purpura (TTP) is a rare
blood condition characterised by the formation of
small clots (thrombi) within the circulation, which
results in the consumption of platelets and thus a low
platelet count (thrombocytopenia).
 What causes TTP?
 DRUG-INDUCED IMMUNE
THROMBOCYTOPENIA
 DRUG-INDUCED IMMUNE
THROMBOCYTOPENIA is a condition where
the use of certain drugs leads to the formation
of antibodies against platelets. These
antibodies can cause a low platelet count,
which make bleeding more likely. If these
antibodies are formed during pregnancy, they
may pass from the mother to the fetus.
 Thrombocytopenia (nonimmune) drug-
induced; Nonimmune
 thrombocytopenia - drug-induced
 Drug-induced nonimmune thrombocytopenia
is a reduction in normally functioning platelets
that can be caused by certain drugs.
 Platelets are important in forming blood clots.
Certain drugs may decrease the number of
platelets by damaging the bone marrow where
platelets are made. Decreased platelets may
cause easy bruising or abnormal bleeding.
 PRIMARY THROMBOCYTHEMIA
 Essential thrombocythemia; Essential
thrombocytosis
 Primary thrombocythemia is a condition of
overproduction of platelets without a
recognizable cause.
Causes, incidence, and risk factors
 Primary thrombocythemia is a slowly progressing
disorder caused by overgrowth of a type of cell that is
a precursor of blood cells. Although the platelets are
primarily affected, the red blood cells and white blood
cells are also involved
 The formation of blood clots, called thrombosis, may
coincide with bleeding episodes.
 It may even cause strokes in some people.
 Risk factors are unknown.
 The incidence is about 3 out of 100,000 people
Symptoms
 Nosebleeds (epistaxis )
 Bleeding from the gums
 Bleeding from the gastrointestinal tract
 Easy bruising
 Prolonged bleeding from surgical procedures or tooth
extraction
 Enlarged lymph nodes (rare)
 Bloody stools
 Headache
 Numbness of hands or feet
 Dizziness
 Ulcers on fingers or toes
 Signs and tests
 Bone marrow aspiration.
 CBC that shows elevated platelet count.
 Uric acid level may be elevated.
 Physical examination may show enlarged
spleen or liver
Treatment
 If a patient is having life-threatening complications-
platelet pheresis.
 Long-term decrease of the platelet count using
medications can reduce both bleeding and clotting
complications.
 Most common medications include hydroxyurea,
interferon-alpha, or anagrelide. For patients with a known
clotting tendency, aspirin may help decrease clotting
episodes.
 Some patients do not need any treatment.
Expectations (prognosis)
 The outcome varies with reports ranging from
prolonged periods without complications in some
people, to fatalities from complications related to
hemorrhage and thrombosis in others.
Complications
 Severe hemorrhage
 Thrombotic episodes (stroke, heart attack, or blood
clots in extremities)
 Acute leukemia or myelofibrosis can develop in some
patients
HYPERSPLENISM
 Hypersplenism is increased activity of the
spleen caused by tumors, anemia, malaria,
tuberculosis, and various connective tissue
and inflammatory diseases.
 An enlarged spleen is often accompanied by
a low level of one or more types of blood
cells. The enlarged spleen can cause
stomach pain on the left side, as well as
feeling full prematurely after eating
DENTAL EVALUATION
good thorough medical historygood thorough medical history
 a physical examination
 screening clinical lab tests
 excessive bleeding following surgical procedure
 Family HX
 Personal HX
 Medications
 Past & Present Illness
 Spontaneous Bleeding
REVIEW PATIENT’S MEDS
 FIVE DRUGS THAT INTERFERE WITH
HEMOSTASIS
 ASPIRIN
 ANTICOAGULANTS
 ANTIBIOTICS
 ALCOHOL
 ANTICANCER
ORAL MANIFESTATIONS
 Petechiae & Ecchymosis
 Gingival Hyperplasia
 Spontaneous Gingival Bleeding
 Ulceration of Oral Mucosa
 Lymphadenopathy
DENTAL PATIENTS
 LOW RISK
 Patients with No Hx of Bleeding Disorders
 Normal Laboratory Results
 MODERATE RISK
 Patients on Chronic Oral Anticoagulant
 Therapy. PT is 1.5 - 2 Times Control Range
 Patients on Chronic Aspirin Therapy
 HIGH RISK
 Patients with Known Bleeding Disorders
 Patients without Known Bleeding Disorders Who Have
Abnormal Laboratory Results
DENTAL MANAGEMENT
 LOW RISK PATIENTS
 Normal Protocol
 MODERATE RISK
PATIENTS
 Anticoagulants -
Consult Physician
 Aspirin Therapy - BT,
Consult Physician
 HIGH RISK PATIENTS
 Close Coordination
with Physician
 Hospitalization (Platelet
Transfusion) (Factor
Replacement)(Vit K
Therapy)(Dialysis
 CONCLUSIONS
 The history (medical /family history) is
extremely important in evaluating patients with
disorders of hemostasis.
 Dental extractions are a very common major
stresses of the haemostatic mechanism, and a
prior history of excessive bleeding following an
extraction is important.
 So, thorough understanding and knowledge
about bleeding disorders is very much needed
for dental professionals to minimize the
complications of many treatment procedures.
References
 Davidson’s “principles and practice of medicine-19th
edition;-Hanslet, Chilvers, Boon, Colledge, Hunters.
 Medical emergencies in the dental practice –malammed;
5th edition
 Bailey and Love’s Short practice of surgery-23rd edition;
Russel, Williams, Bulstrode;
 Complications in Oral and Maxillofacial surgery-1st edition;
Kaban, Pogrel, Perrot.
 Concise Medical Physiology;-5th edition; Chaudhari
 Systemic disease in dental treatment-1st edition;-
Michael.J.Tullman, Spencer.W.Redding.
 Clinical hematology-7th edition;-Maxwell.M.Wintrobe.
 www.hemophilia.org
 www.google.com
Thank you

Weitere ähnliche Inhalte

Was ist angesagt?

Oral consideration and laboratory investigations of bleeding and clotting dis...
Oral consideration and laboratory investigations of bleeding and clotting dis...Oral consideration and laboratory investigations of bleeding and clotting dis...
Oral consideration and laboratory investigations of bleeding and clotting dis...kashmira483
 
Coagulation of blood and bleeding disorders
Coagulation of blood and bleeding disordersCoagulation of blood and bleeding disorders
Coagulation of blood and bleeding disordersDr. Mounika Pininti
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation DisordersGhie Santos
 
Hemostasis and blood coagulation general pathology
Hemostasis and blood  coagulation general pathologyHemostasis and blood  coagulation general pathology
Hemostasis and blood coagulation general pathologySiganga Siganga
 
hematology.wustl.edu/conferences/presentations/bli... hematology.wustl.edu/...
hematology.wustl.edu/conferences/presentations/bli... 	 hematology.wustl.edu/...hematology.wustl.edu/conferences/presentations/bli... 	 hematology.wustl.edu/...
hematology.wustl.edu/conferences/presentations/bli... hematology.wustl.edu/...MedicineAndHealthCancer
 
Bleeding and clotting disorders
Bleeding and clotting disordersBleeding and clotting disorders
Bleeding and clotting disordersUMAMAHISHAQ
 
Normal hemostasis and coagulation
Normal hemostasis and coagulationNormal hemostasis and coagulation
Normal hemostasis and coagulationwendwesen alemu
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation DisordersAbhineet Dey
 
Von Willebrand Disease
Von Willebrand DiseaseVon Willebrand Disease
Von Willebrand DiseaseLawchak Mhamad
 
Blood coagulation cascade
Blood coagulation cascadeBlood coagulation cascade
Blood coagulation cascadeBangaluru
 
Approach to patients with bleeding disorders
Approach to patients with bleeding disordersApproach to patients with bleeding disorders
Approach to patients with bleeding disordersAYM NAZIM
 

Was ist angesagt? (20)

Hemostasis
HemostasisHemostasis
Hemostasis
 
Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
 
Platelet disoders
Platelet disodersPlatelet disoders
Platelet disoders
 
Oral consideration and laboratory investigations of bleeding and clotting dis...
Oral consideration and laboratory investigations of bleeding and clotting dis...Oral consideration and laboratory investigations of bleeding and clotting dis...
Oral consideration and laboratory investigations of bleeding and clotting dis...
 
Coagulation of blood and bleeding disorders
Coagulation of blood and bleeding disordersCoagulation of blood and bleeding disorders
Coagulation of blood and bleeding disorders
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation Disorders
 
Haemostasis
HaemostasisHaemostasis
Haemostasis
 
Hemostasis and blood coagulation general pathology
Hemostasis and blood  coagulation general pathologyHemostasis and blood  coagulation general pathology
Hemostasis and blood coagulation general pathology
 
Disorders of Platelets
Disorders of PlateletsDisorders of Platelets
Disorders of Platelets
 
hematology.wustl.edu/conferences/presentations/bli... hematology.wustl.edu/...
hematology.wustl.edu/conferences/presentations/bli... 	 hematology.wustl.edu/...hematology.wustl.edu/conferences/presentations/bli... 	 hematology.wustl.edu/...
hematology.wustl.edu/conferences/presentations/bli... hematology.wustl.edu/...
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
Thrombocytopenia
 
Bleeding and clotting disorders
Bleeding and clotting disordersBleeding and clotting disorders
Bleeding and clotting disorders
 
Normal hemostasis and coagulation
Normal hemostasis and coagulationNormal hemostasis and coagulation
Normal hemostasis and coagulation
 
Coagulation cascade
Coagulation cascadeCoagulation cascade
Coagulation cascade
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation Disorders
 
Von Willebrand Disease
Von Willebrand DiseaseVon Willebrand Disease
Von Willebrand Disease
 
Blood coagulation cascade
Blood coagulation cascadeBlood coagulation cascade
Blood coagulation cascade
 
Platelet disorders
Platelet disordersPlatelet disorders
Platelet disorders
 
Tests of bleeding disorders
Tests of bleeding disordersTests of bleeding disorders
Tests of bleeding disorders
 
Approach to patients with bleeding disorders
Approach to patients with bleeding disordersApproach to patients with bleeding disorders
Approach to patients with bleeding disorders
 

Ähnlich wie Bleeding Disorders: Causes, Types, and Diagnosis

Aproach to bleeding disorder in Pediatrics
Aproach to bleeding disorder in Pediatrics Aproach to bleeding disorder in Pediatrics
Aproach to bleeding disorder in Pediatrics Aregahegn Tadesse
 
Demands for Haemophilia tratment centres to fullfull universal health access...
Demands for Haemophilia  tratment centres to fullfull universal health access...Demands for Haemophilia  tratment centres to fullfull universal health access...
Demands for Haemophilia tratment centres to fullfull universal health access...SEJOJO PHAAROE
 
How to approach a child with bleeding disorder
How to approach a child with bleeding disorderHow to approach a child with bleeding disorder
How to approach a child with bleeding disorderKamran Akbar
 
Bleeding, clotting,platelet disorder and it's management
Bleeding, clotting,platelet disorder and it's managementBleeding, clotting,platelet disorder and it's management
Bleeding, clotting,platelet disorder and it's managementRakhiYadav53
 
HAEMOPHELIA.pptx
HAEMOPHELIA.pptxHAEMOPHELIA.pptx
HAEMOPHELIA.pptxsalman khan
 
Prevsirjoh medical university hemophilia
Prevsirjoh medical university  hemophiliaPrevsirjoh medical university  hemophilia
Prevsirjoh medical university hemophiliaJohnLubutwe
 
Dental Management of Patients with Bleeding Disorders
Dental Management of Patients with Bleeding DisordersDental Management of Patients with Bleeding Disorders
Dental Management of Patients with Bleeding DisordersDr Afsal S M
 
Hematology lect 3
Hematology lect 3Hematology lect 3
Hematology lect 3Miami Dade
 
clinical approach to patients with bleeding tendency
clinical approach to patients with bleeding tendencyclinical approach to patients with bleeding tendency
clinical approach to patients with bleeding tendencyReem Alyahya
 
Presantation on bleeding disorder in pediatric patients
Presantation on bleeding disorder in pediatric patientsPresantation on bleeding disorder in pediatric patients
Presantation on bleeding disorder in pediatric patientsSiraj Shiferaw
 
Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)student
 
Perioperative bleeding and Hemostasis
Perioperative bleeding and HemostasisPerioperative bleeding and Hemostasis
Perioperative bleeding and Hemostasisalmemon
 

Ähnlich wie Bleeding Disorders: Causes, Types, and Diagnosis (20)

Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
 
Aproach to bleeding disorder in Pediatrics
Aproach to bleeding disorder in Pediatrics Aproach to bleeding disorder in Pediatrics
Aproach to bleeding disorder in Pediatrics
 
Demands for Haemophilia tratment centres to fullfull universal health access...
Demands for Haemophilia  tratment centres to fullfull universal health access...Demands for Haemophilia  tratment centres to fullfull universal health access...
Demands for Haemophilia tratment centres to fullfull universal health access...
 
Hemophilia
HemophiliaHemophilia
Hemophilia
 
How to approach a child with bleeding disorder
How to approach a child with bleeding disorderHow to approach a child with bleeding disorder
How to approach a child with bleeding disorder
 
Bleeding, clotting,platelet disorder and it's management
Bleeding, clotting,platelet disorder and it's managementBleeding, clotting,platelet disorder and it's management
Bleeding, clotting,platelet disorder and it's management
 
Hemmoragic disorder
Hemmoragic disorderHemmoragic disorder
Hemmoragic disorder
 
Haemorrhage
HaemorrhageHaemorrhage
Haemorrhage
 
Hemophilia a
Hemophilia aHemophilia a
Hemophilia a
 
HAEMOPHELIA.pptx
HAEMOPHELIA.pptxHAEMOPHELIA.pptx
HAEMOPHELIA.pptx
 
Prevsirjoh medical university hemophilia
Prevsirjoh medical university  hemophiliaPrevsirjoh medical university  hemophilia
Prevsirjoh medical university hemophilia
 
Dental Management of Patients with Bleeding Disorders
Dental Management of Patients with Bleeding DisordersDental Management of Patients with Bleeding Disorders
Dental Management of Patients with Bleeding Disorders
 
Bleeding child
Bleeding childBleeding child
Bleeding child
 
Hematology lect 3
Hematology lect 3Hematology lect 3
Hematology lect 3
 
clinical approach to patients with bleeding tendency
clinical approach to patients with bleeding tendencyclinical approach to patients with bleeding tendency
clinical approach to patients with bleeding tendency
 
Presantation on bleeding disorder in pediatric patients
Presantation on bleeding disorder in pediatric patientsPresantation on bleeding disorder in pediatric patients
Presantation on bleeding disorder in pediatric patients
 
Hemophilia
HemophiliaHemophilia
Hemophilia
 
Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)
 
Hemophilia
Hemophilia Hemophilia
Hemophilia
 
Perioperative bleeding and Hemostasis
Perioperative bleeding and HemostasisPerioperative bleeding and Hemostasis
Perioperative bleeding and Hemostasis
 

Mehr von Dr Medical

Epidemiology of periodontal diseases
Epidemiology of periodontal diseasesEpidemiology of periodontal diseases
Epidemiology of periodontal diseasesDr Medical
 
Epidemiology of oral cancer
Epidemiology of oral cancerEpidemiology of oral cancer
Epidemiology of oral cancerDr Medical
 
Dentist patient relationship and quality care
Dentist patient relationship and quality careDentist patient relationship and quality care
Dentist patient relationship and quality careDr Medical
 
Genetic counselling - a review
Genetic counselling - a reviewGenetic counselling - a review
Genetic counselling - a reviewDr Medical
 
Finance in dental care
Finance in dental careFinance in dental care
Finance in dental careDr Medical
 
Physiology of body fluids
Physiology of body fluidsPhysiology of body fluids
Physiology of body fluidsDr Medical
 
The General Pain Pathways
The General Pain PathwaysThe General Pain Pathways
The General Pain PathwaysDr Medical
 
Oral mucous membrane - Oral mucosa
Oral mucous membrane - Oral mucosaOral mucous membrane - Oral mucosa
Oral mucous membrane - Oral mucosaDr Medical
 
Social and Behavioral sciences
Social and Behavioral sciencesSocial and Behavioral sciences
Social and Behavioral sciencesDr Medical
 
Antifluoridation lobby - Water fluoridation controversy
Antifluoridation lobby - Water fluoridation controversyAntifluoridation lobby - Water fluoridation controversy
Antifluoridation lobby - Water fluoridation controversyDr Medical
 
Breastfeeding pacifiers pros and cons
Breastfeeding pacifiers pros and consBreastfeeding pacifiers pros and cons
Breastfeeding pacifiers pros and consDr Medical
 
Non Pharmacological Behavior Management
Non Pharmacological Behavior ManagementNon Pharmacological Behavior Management
Non Pharmacological Behavior ManagementDr Medical
 
Anemia Causes, Types, Symptoms, Diet, and Treatment
Anemia Causes, Types, Symptoms, Diet, and Treatment Anemia Causes, Types, Symptoms, Diet, and Treatment
Anemia Causes, Types, Symptoms, Diet, and Treatment Dr Medical
 
Anthropology and oral health
Anthropology and oral healthAnthropology and oral health
Anthropology and oral healthDr Medical
 
Recent advances in preventive dentistry
Recent advances in preventive dentistryRecent advances in preventive dentistry
Recent advances in preventive dentistryDr Medical
 
Anomalies of the first and second branchial arches
Anomalies of the first and second branchial archesAnomalies of the first and second branchial arches
Anomalies of the first and second branchial archesDr Medical
 
Ankyloglossia a congenital oral anomaly
Ankyloglossia a congenital oral anomaly Ankyloglossia a congenital oral anomaly
Ankyloglossia a congenital oral anomaly Dr Medical
 

Mehr von Dr Medical (17)

Epidemiology of periodontal diseases
Epidemiology of periodontal diseasesEpidemiology of periodontal diseases
Epidemiology of periodontal diseases
 
Epidemiology of oral cancer
Epidemiology of oral cancerEpidemiology of oral cancer
Epidemiology of oral cancer
 
Dentist patient relationship and quality care
Dentist patient relationship and quality careDentist patient relationship and quality care
Dentist patient relationship and quality care
 
Genetic counselling - a review
Genetic counselling - a reviewGenetic counselling - a review
Genetic counselling - a review
 
Finance in dental care
Finance in dental careFinance in dental care
Finance in dental care
 
Physiology of body fluids
Physiology of body fluidsPhysiology of body fluids
Physiology of body fluids
 
The General Pain Pathways
The General Pain PathwaysThe General Pain Pathways
The General Pain Pathways
 
Oral mucous membrane - Oral mucosa
Oral mucous membrane - Oral mucosaOral mucous membrane - Oral mucosa
Oral mucous membrane - Oral mucosa
 
Social and Behavioral sciences
Social and Behavioral sciencesSocial and Behavioral sciences
Social and Behavioral sciences
 
Antifluoridation lobby - Water fluoridation controversy
Antifluoridation lobby - Water fluoridation controversyAntifluoridation lobby - Water fluoridation controversy
Antifluoridation lobby - Water fluoridation controversy
 
Breastfeeding pacifiers pros and cons
Breastfeeding pacifiers pros and consBreastfeeding pacifiers pros and cons
Breastfeeding pacifiers pros and cons
 
Non Pharmacological Behavior Management
Non Pharmacological Behavior ManagementNon Pharmacological Behavior Management
Non Pharmacological Behavior Management
 
Anemia Causes, Types, Symptoms, Diet, and Treatment
Anemia Causes, Types, Symptoms, Diet, and Treatment Anemia Causes, Types, Symptoms, Diet, and Treatment
Anemia Causes, Types, Symptoms, Diet, and Treatment
 
Anthropology and oral health
Anthropology and oral healthAnthropology and oral health
Anthropology and oral health
 
Recent advances in preventive dentistry
Recent advances in preventive dentistryRecent advances in preventive dentistry
Recent advances in preventive dentistry
 
Anomalies of the first and second branchial arches
Anomalies of the first and second branchial archesAnomalies of the first and second branchial arches
Anomalies of the first and second branchial arches
 
Ankyloglossia a congenital oral anomaly
Ankyloglossia a congenital oral anomaly Ankyloglossia a congenital oral anomaly
Ankyloglossia a congenital oral anomaly
 

Kürzlich hochgeladen

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 

Kürzlich hochgeladen (20)

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 

Bleeding Disorders: Causes, Types, and Diagnosis

  • 1. BLEEDING DISORDERS Check out ppt download link in description Or Download link : https://userupload.net/wxvqfbo7ywqu
  • 2. CONTENTS… Introduction History - A Royal Disease Finding the cause Identifying clotting factors Hemostasis Bleeding disorders -Vascular disorders -Coagulation disorders -Platelet disorders Dental Evaluation Dental management Conclusions References
  • 4. History • In the Talmud, 2nd century AD •A 12th century Arab physician named Albucasis •In the U.S., the transmission of hemophilia from mothers to sons was first described in the early 1800s. •In 1803, a Philadelphia physician named Dr. John Conrad Otto wrote an account of "a hemorrhagic disposition existing in certain families." • The word "Hemophilia" first appeared in a description of a bleeding disorder condition at the University of Zurich in 1828.
  • 5. CLICK HERE TO DOWNLOAD THIS PPT https://userupload.net/wxvqfbo7ywqu
  • 7. Finding the Cause  In the 20th century doctors looked for the cause of excessive bleeding. Until then, they had believed that the blood vessels of hemophiliacs were simply more fragile.  1925 Although it is probably the most common hereditary bleeding disorder (affecting approximately 1% to 2% of the population), von Willebrand disease was not recognized until 1925.
  • 8.  1937, Patek and Taylor, two doctors at Harvard, They called it "anti-hemophilic globulin."  1944 Pavlosky, a doctor from Buenos Aires, Argentina, did a lab test which showed that blood from one hemophilic patient could correct the clotting problem in a second and vice-versa.
  • 9. Identifying Clotting Factors  In the 1960s the clotting factors were identified and named.  An article in Nature in 1964  In the 1950s and early 1960s, hemophilia and other bleeding problems were treated with whole blood or fresh plasma. Unfortunately, there wasn't enough of the factor VIII or IX proteins in these blood products to stop serious internal bleeding.  Then, in the 1960s, cryoprecipitate was discovered by Dr. Judith Pool
  • 10. CLICK HERE TO DOWNLOAD THIS PPT https://userupload.net/wxvqfbo7ywqu
  • 11.  Then, later in the 1960s and early 1970s, concentrates containing factor VIII and IX began to be available. (freeze-dried powdered concentrates)  blood products carried blood-borne viruses like hepatitis C and HIV.  In the 1990s, modern treatment, using safer factor concentrates, has again improved the outlook
  • 12. Recent progress includes: • New clotting factor products and drugs such as desmopressin acetate also known as DDAVP, • New, synthetic (not derived from plasma) clotting products that take advantage of recombinant technologies • Better screening methods to detect and remove viruses and other agents from factor concentrates and blood products • Improved surgical options • Advanced genetic testing methods • Medically supervised home-infusion therapy • Prophylactic treatment
  • 14. Platelets-origin Life span : 7-14 days Site of destruction: Spleen Normal count : 1.5 - 4.5 lacks / cc Increase in count : Thrombocytosis Decrease in count : Thrombocytopenia Decrease in platelet count below 40,000is associated with hemorrhagic disorders.
  • 15. CLICK HERE TO DOWNLOAD THIS PPT https://userupload.net/wxvqfbo7ywqu
  • 16. a. Physiological Variations :  Seasonal - Count is more during winter season.  Pregnancy - Count decrease  Exercise, excitement, injection of adrenaline, high altitude - Increased count. b. Pathological Variations :  Increased platelet count seen after splenectomy idiopathic.  Decreased platelet count is seen in  Viral infection  Aplastic anaemia  Idiopathic
  • 17. HEMOSTASIS  Primary Hemostasis  Blood vessel contraction  Platelet Plug Formation  Secondary Hemostasis  Activation of Clotting Cascade  Deposition & Stabilization of Fibrin  Tertiary Hemostasis  Dissolution of Fibrin Clot  Dependent on Plasminogen Activation
  • 18. Detailed Events of Coagulation Figure 17.13b
  • 22. Tests of Hemostasis:  Screening tests:  Bleeding.T - 10m. Platelet & BV function  Prothrombin.T – Extrinsic, aPTT – Instrinsic  Thrombin.T – common path. (DIC)  Specific tests:  Factor assays – hemophilia.  Tests of thrombosis – TT,  Platelet function studies: Adhesion, Aggregation, Release tests.  Bone Marrow study
  • 23. Disorders of Hemostasis Classification : • Disorders of Blood vessels • Scurvy, senile purpura, Henoch-Schonlein syndrome. • Disorders of Platelets • Thrombocytopenia ITP, TTP, HUS, DIC. • Aspirin therapy, Thrombasthenia, • Disorders of Coagulation • Extrinsic, intrinsic, combined. • Other disorders • Post transfusion purpura.
  • 24. Vascular disorders: Petechiae, purpura, ecchymoses senile purpura vitamin C deficiency (scurvy) Connective tissue disorders Infections – Meningococcus Henoch-Schonlein Purpura-Immu
  • 27. Petechiae inPetechiae in VasculitisVasculitis (Rocky Mountain Spotted Fever)(Rocky Mountain Spotted Fever)
  • 28. Henoch-Schonlein purpura  Immune disorder  Children  Follows infection  Petechiae with edema and itching.
  • 29. Henoch-Schonlein purpura 20y Male, fever, painful symmetric polyarthritis for a day. During the next two days, edema and palpable purpura developed.
  • 30. Disorders of coagulation  Hemophilia A(Factor VIII Deficiency)  What Is It? The incidence of hemophilia A is one in 10,000 live male births. About 17,000 Americans have hemophilia.
  • 31. Inheritance Pattern  Hemophilia A is caused by an inherited sex- linked recessive trait with the defective gene located on the X chromosome.
  • 33. Genetic counseling may be advised for carriers.  Female carriers can be identified by testing.  A woman is definitely a hemophilia carrier if she is: • the biological daughter of a man with hemophilia; • the biological mother of more than one son with hemophilia; • the biological mother of one hemophilic son who has at least one other blood relative with hemophilia. A woman may or may not be a hemophilia carrier if she is: • the biological mother of one son with hemophilia; • the sister of a male with hemophilia; • an aunt, cousin or niece of an affected male related through maternal ties; • the biological grandmother of one grandson with hemophilia.
  • 34. Symptoms & Diagnosis  Bruising  Spontaneous bleeding  Bleeding into joints and associated pain and swelling  Gastrointestinal tract and urinary tract hemorrhage  Blood in the urine or stool  Prolonged bleeding from cuts, tooth extraction, and surgery  People whose clotting activity is 5 percent of normal may have only mild hemophilia.
  • 36. Treatments  In the past, mild hemophilia A was typically treated with infusion of cryoprecipitate or desmopressin acetate (DDAVP),  . Today, experts recommend desmopressin injection or Stimate nasal spray.  cryoprecipitate
  • 37.  Depending on the severity of the disease, DDAVP or factor VIII concentrate -prior to dental extractions and surgery to prevent bleeding.  Immunization with hepatitis B vaccine.  Gene therapy and fetal tissue implant techniques  People who have hemophilia should also avoid certain drugs that can aggravate bleeding problems:  Aspirin  Heparin  Warfarin  Certain analgesics such as nonsteroidal anti- inflammatory drugs
  • 38.  MASAC made recommendations for treatment of hemophilia in November of 1999. They include: 1. Factor VIII products for patients who are HIV seronegative, including Recombinant factor VIII, 2. Immunoaffinity purified factor VIII concentrates 3. Cryoprecipitate is not recommended because of the risk of HIV and hepatitis infection. 4. Mild hemophilia A should be treated with desmopressin, in a DDAVP injection or Stimate nasal spray.
  • 39. complications  Chronic joint deformities  Intracerebral hemorrhage
  • 40. Hemophilia B (Factor IX Deficiency)  . Hemophilia B ("Christmas disease" )  Is a deficiency in clotting factor IX.  Hemophilia A is seven times more common than hemophilia B.  The incidence of hemophilia B is one in 34,500 men.
  • 41.  Inheritance Pattern  Hemophilia B is caused by an inherited sex- linked recessive trait with the defective gene located on the X chromosome. Females are carriers of this trait.
  • 42. Genetic counseling may be advised for carriers. Female carriers can be identified by testing. A woman is definitely a hemophilia carrier if she is:  the biological daughter of a man with hemophilia;  the biological mother of more than one son with hemophilia; • the  biological mother of one son with hemophilia and has at least one other  blood relative with hemophilia. A woman may or may not be a hemophilia carrier if she is:  the biological mother of one son with hemophilia;  the sister of a male with hemophilia;  an aunt, cousin or niece of an affected male related through maternal ties;  the biological grandmother of one grandson with hemophilia.
  • 43. Symptoms include:  nosebleeds  bruising  spontaneous bleeding  bleeding into joints and associated pain and swelling  gastrointestinal tract and urinary tract hemorrhage  blood in the urine or stool  prolonged bleeding from cuts, tooth extraction and surgery  prolonged bleeding following circumcision  People whose clotting activity is 5% of normal may have only mild hemophilia.
  • 44. DIAGNOSIS:  A doctor may suspect hemophilia in a child whose bleeding is unusual.  A laboratory analysis of blood samples  Determine the severity by testing the activity of factor IX.
  • 45. Treatments • Infusing the missing clotting factor. • To prevent a bleeding crisis- taught to administer factor IX concentrates at home at the first signs of bleeding. • Factor IX concentrate may be given prior to dental extractions and surgery to prevent bleeding. • Milder forms of hemophilia need to have dental or other surgery, the drug desmopressin acetate (DDAVP) may be given to improve clotting temporarily so that transfusions can be avoided.
  • 46. MASAC made recommendations for treatment of hemophilia B in November of 1999. They include • Recombinant factor IX products for patients who are HIV seronegative, • Patients who are HIV-seropositive should also be treated with high purity products such as immunoaffinity purified and recombinant factor VIII products. • For patients with inhibitors to factors VIII and IX, there is Recombinant Factor VIIa (NovoSeven). Produced by baby hamster kidney cells, no human albumin or other proteins are used in its production, reducing virus risk. There is also Porcine factor VIII (Hyate C) and activated prothrombin complex concentrates
  • 47. Complications • Chronic joint deformities, • Intracerebral hemorrhage may also occur. • Thrombosis may occur following use of factor IX concentrate.
  • 48.  Von Willebrand Disease  What Is It?  von Willebrand disease is a hereditary deficiency or abnormality of the von Willebrand factor in the blood, a protein that affects platelet function
  • 50.  Researchers have identified many variations of the disease, but most fall into the following classifications • Type I: This is the most common and mildest form of von Willebrand disease. Levels of von Willebrand factor are lower than normal, and levels of factor VIII may also be reduced. • Type II: In these people, the von Willebrand factor itself has an abnormality. Depending on the abnormality, they may be classified as having Type IIa or Type IIb. In Type IIa, the level of von Willebrand factor is reduced, as is the ability of platelets to clump together. In Type IIb, although the factor itself is defective, the ability of platelets to clump together is actually increased.
  • 51.  Type III: This is severe von Willebrand disease. These people may have a total absence of von Willebrand factor, and factor VIII levels are often less than 10%.  Pseudo (or platelet-type) von Willebrand disease: This disorder resembles Type IIb von Willebrand disease, but the defects appears to be in the platelets, rather than the von Willebrand factor.
  • 52.  Inheritance Pattern Like hemophilia, the disease is passed down through the genes. occurs in men and women equally. Types I and II are usually inherited in what is known as a "dominant" pattern. Type III von Willebrand disease, however, is usually inherited in a "recessive" pattern.
  • 53.  Symptoms and Diagnosis  A parent with a history of bleeding problems.  Typically, a child bruises easily or has bleeds excessively after a skin cut, tooth extraction, tonsillectomy or other surgery.  A woman may have increased menstrual bleeding. Bleeding may worsen at times.  On the other hand, hormonal changes, stress, pregnancy, inflammation and infections may stimulate the body to increase production of the von Willebrand factor and temporarily improve clot formation.
  • 54. Diagnostic signs can include:  normal platelet count  prolonged bleeding time  reduced von Willebrand factor level  reduced platelet adhesion may occur  reduced or increased platelet aggregation (platelet aggregation test)  ristocetin cofactor is reduced
  • 55. MASAC made recommendations for treatment of von Willebrand disease in November of 1999. They include: • Stimate, desmopressin acetate. (DDAVP),nasal spray or injection • Viral-inactivated factor VIII preparations rich in von Willebrand factor, such as Alphanate, Humate-P and Koate DVI, are recommended. • Cryoprecipitate is not recommended except in life-threatening emergencies because of the risk of HIV and hepatitis infection.
  • 56.  Complications After any kind of surgery, hemorrhaging may occur. The condition is worsened by the use of aspirin and other nonsteroidal anti-inflammatory drugs. Women may have heavy menstrual periods as well as risks during pregnancy and childbirth. .
  • 57.  Factor I Deficiency (Afibrinogenemia)  What Is It?  Fibrinogen, also known as factor I, is needed for most types of platelet aggregation. It's the last step in the clotting process—the "glue" that holds the clot together.
  • 58.  Included under factor I deficiency are several rare coagulation disorders known as congenital fibrinogen defects. They include: • afibrinogenemia • hypofibrinogenemia • dysfibrinogenemia
  • 59.  Inheritance Pattern  The disorder is not sex-linked  It affects both males and females with equal frequency.  It is autosomal recessive.
  • 60.  Symptoms and Diagnosis Few people who have any of these disorders suffer symptoms, although some are predisposed to form blood clots (thrombosis).
  • 61.  Treatments -Many people with hypofibrinogenemia or dysfibrinogenemia need no treatment. -Those who require treatment may be given cryoprecipitate or fresh frozen plasma. The goal of treatment is to raise the patient's fibrinogen level to 100 mg/dL for minor bleeding and up to 200 mg/dL for surgery or severe bleeding. (One unit of fresh frozen plasma has about 450 mg of fibrinogen.)
  • 62.  Complications -Risk of thrombosis. -In women, menstrual bleeding can be a severe problem and must be controlled
  • 63. Factor II Deficiency(Prothrombin)  What Is It?  Prothrombin is a vitamin K-dependent proenzyme that functions in coagulation. 1)a congenital version called hypoprothrombinemia, 2)acquired version called dysprothrombinemia.
  • 64.  congenital, factor II deficiency is extremely rare.  Acquired factor II deficiency is more common. It results from vitamin K deficiency, severe liver disease and therapeutic use of anticoagulant drugs.
  • 65.  Inheritance Pattern  A congenital factor II deficiency is a very rare inherited disorder that results in deficient blood clotting. The disorder is not sex-linked as is hemophilia.  It affects both males and females with equal frequency.  It is autosomal recessive,
  • 66. Symptoms include: • umbilical cord bleeding at birth • nose bleeds • abnormal menstrual bleeding • abnormal bleeding after delivery • bleeding after trauma • bleeding after surgery • easy bruising Signs and Tests: • prolonged prothrombin time • prolonged partial thromboplastin time • factor II assay showing decreased activity • levels of prothrombin ranging from 2% to 50% of normal
  • 67. Treatments MASAC made recommendations for treatment of factor II deficiency in November of 1999. They include: • Prothrombin complex concentrates (PCCs) can be used, but these products vary considerably in the amount of factors they contain. • Fresh frozen plasma can be used as along as it is processed to reduce the risk of viral infection.
  • 68.  Complications Bleeding has to be controlled in instances of trauma or surgery, or else bleeding into the brain or skull can occur.
  • 69.  Factor V Deficiency (Para hemophilia) What Is It?  Factor V deficiency is also known as Owren's disease or parahemophilia.  This deficit was identified in Norway in 1943. Since then about 150 cases have been reported, occurring in both men and women. The exact frequency of this rare disorder is unknown, but is estimated to be one per 1 million
  • 70.  Inheritance Pattern  The disorder is not sex-linked as is hemophilia.  It affects both males and females with equal frequency.  It is autosomal recessive,  Several families with combined deficiencies of factors V and VIII have been reported.
  • 71. Symptoms and Diagnosis Symptoms include:  bleeding into the skin  excessive bruising with minor injuries  nose bleeds  bleeding of the gums  excessive menstrual bleeding  prolonged or excessive loss of blood with surgery or trauma Diagnosing the deficiency involves tests and signs such as:  factor V assay showing decreased activity  slightly prolonged bleeding time (in some people)  prolonged partial thromboplastin time  prolonged prothrombin time
  • 72. Treatments -There are no commercially available concentrates of factor V, so fresh plasma or fresh frozen plasma infusions are used . -The half-life of factor V is 24 hours. -This is an inherited disorder; there is no known prevention.  Complications -Dangerous hemorrhaging can occur if bleeding isn't controlled quickly. - If platelets are used as a source of factor V, antiplatelet antibodies can be induced.
  • 73.  Factor VII Deficiency (Proconvertin or Stable Factor)  What Is It?  This extremely rare disorder can be inherited or acquired by people who do not have hemophilia who take Coumadin, a drug used to inhibit blood clotting.
  • 74.  This disorder occurs in one in 500,000 males and females.  Congenital factor VII deficiency should be distinguished from acquired factor VII deficiency, which may result from liver disease, vitamin K deficiency or other malabsorption conditions.
  • 75.  Inheritance Pattern  The disorder is not sex-linked as is hemophilia.  It affects both males and females with equal frequency.  It is also autosomal recessive,  Those who have inherited a defective factor VII gene from only one parent will usually have only moderate levels of the factor but no symptoms.
  • 76. Symptoms and Diagnosis Symptoms include: • bleeding of mucous membranes • spontaneous nosebleeds • excessive bruising • prolonged menstrual bleeding • bleeding into muscles • bleeding into joints Diagnosis is made by testing for factor VII in the blood.
  • 77. • Signs and tests include: -prolonged prothrombin time -- normal partial thromboplastin time -- decreased factor VII assay
  • 78. MASAC made recommendations for treatment of Factor VII deficiency in November of 1999. They include: • Recombinant factor VIIa (NovoSeven). • Prothrombin complex concentrates (PCCs) can be used, but these products vary considerably in the amount of factors they contain. • Fresh frozen plasma can be used as along as it is processed to reduce the risk of viral infection. TREATMENTS
  • 79. Complications These can include hemorrhages, strokes or other neurological problems related to central nervous system bleeding. • Fatal intracranial bleeding caused by birth trauma has occurred. • Menstrual bleeding may also be severe.
  • 80. THROMBOCYTOPENIA  Definition  Thrombocytopenia is any disorder in which there are not enough platelets. Platelets are cells in the blood that help blood to clot. This condition is sometimes associated with abnormal bleeding.
  • 81.  Causes, incidence, and risk factors Thrombocytopenia is often divided into three major causes of low platelets: 1) Low production of platelets in the bone marrow 2) Increased breakdown of platelets in the bloodstream (called intravascular) 3) Increased breakdown of platelets in the spleen or liver (called extravascular
  • 82. 1)Disorders that involve low production in the bone marrow include: -Aplastic anemia -Cancer in the bone marrow -Infections in the bone marrow (rare) -Drugs (very rare)
  • 83. 2)Disorders that involve the breakdown of platelets include:  Immune thrombocytopenic purpura (ITP)  Drug-induced immune thrombocytopenia  Drug-induced nonimmune thrombocytopenia  Thrombotic thrombocytopenic purpura  Primary thrombocythemia  Disseminated intravascular coagulation (DIC)  Hypersplenism (an enlarged spleen)
  • 84.  Symptoms -Bruising -Nose bleeds or bleeding in the mouth ` -Rash (pinpoint red spots) -Other symptoms may be present as well, depending on the cause of the condition. Mild thrombocytopenia can occur without symptoms.
  • 85.  Signs and tests -CBC shows low platelets -Bone marrow aspiration or Biopsy may be normal or may show low megakaryocytes (platelet precursors) or an infiltrating disease. -PTTclotting study is normal -PTclotting study is normal -Platelet associated antibodies may be present
  • 86.  Treatment Treatment depends on the cause of the condition. In some cases, a transfusion of platelets may be required to stop or prevent bleeding. Expectations (prognosis) The outcome depends on the disorder causing the low platelet counts. Complications - Hemorrhage -Gastro intestinal blleding -Bleeding in the brain (intracranial hemorrhage)
  • 87. DISSEMINATED INTRAVASCULAR COAGULATION  DIC is a syndrome arising as a complication of many different serious and life-threatening illnesses. 1) Acute (overt) form it is a hemorrhagic disorder, 2) Chronic (nonovert) DIC, on the other hand, is more subtle and involves thromboembolism accompanied by evidence of activation of the coagulation system.
  • 89. Table 1. Conditions underlying DIC syndrome  Infections Acute DIC: Bacteria and their toxins, fungi, viruses, rickettsiae Chronic DIC: Any chronic infection (eg, tuberculosis, abscesses, osteomyelitis)  Noninfectious inflammatory diseases Inflammatory bowel disease: Crohn's disease and similar disorders  Obstetrical complications Acute DIC: Abruptio placentae, abortions (especially therapeutic abortions), amniotic fluid embolism, hemorrhagic shock Chronic DIC: Dead fetus syndrome  Malignancy Acute DIC: Acute promyelocytic leukemia, acute myelomonocytic or monocytic leukemia, disseminated prostatic carcinoma Chronic DIC: Lung, breast, gastrointestinal malignancy
  • 90.  Vascular disease Acute DIC: Brain infarction or hemorrhage Chronic DIC: Aortic aneurysm, giant hemangioma  Venoms Acute DIC: Snake, spider (rare)  Trauma ;  Acute DIC: Massive tissue destruction, brain damage  Others Acute DIC: Heparin-induced thrombocytopenia with thrombosis (HITT), purpura fulminans in newborns (homozygous protein C deficiency)zDIC, disseminated intravascular coagulation.
  • 91. Clinical and laboratory findings in DIC  Acute DIC Clinical findings  Multiple bleeding sites  Ecchymoses of skin, mucous membranes  Visceral hemorrhage  Ischemic tissue
  • 92. Laboratory abnormalities  Coagulation abnormalities:  prolonged prothrombin time,  activated partial thromboplastin time,  thrombin time; decreased fibrinogen levels; increased levels of FDP (eg, on testing for FDP, D dimer)  Platelet count decreased as a rule but may be falling from a higher level yet still be normal  Schistocytes on peripheral smear
  • 93. Clinical and laboratory findings in DIC  Chronic DIC Clinical findings  Signs of deep venous or arterial thrombosis or embolism  Superficial venous thrombosis, especially without varicose veins  Multiple thrombotic sites at the same time  Serial thrombotic episodes
  • 94. Laboratory abnormalities  Modestly increased prothrombin time in some patients  Shortened or lengthened partial thromboplastin time  Normal thrombin time in most patients  High, normal, or low fibrinogen level  High, normal, or low platelet count  Increased levels of FDP (eg, on testing for FDP, D dimer)  Evidence of molecular markers* (eg, thrombin-antithrombin complexes, activation markers on platelet membranes, prothrombin fragment F1+2)
  • 95. Treatment options for DIC syndrome  . Treat the underlying disease Avoid delay Treat vigorously (eg, shock, sepsis, obstetrical problems)  Manage the DIC Acute DIC Without bleeding or evidence of ischemia No treatment With bleeding Blood components as needed Fresh frozen plasma Cryoprecipitate Platelet transfusions With ischemia Anticoagulants (see "with thromboembolism" below) after bleeding risk is corrected with blood products
  • 96. Chronic DIC  Without thromboembolism No specific therapy needed but prophylactic drugs (eg, low-dose heparin, low-molecular-weight heparin)  With thromboembolism Heparin or low-molecular-weight heparin, trial of warfarin sodium (Coumadin).  *Some patients respond to warfarin, others do not. Use of low-molecular-weight heparin for prolonged periods has potential hazards and is expensive but can be useful when warfarin therapy fails despite good control (international normalized ratio [INR], 2-3).
  • 98.  What causes ITP?  Who gets ITP?  How does ITP affect children?  How is ITP diagnosed?  How is ITP treated in children?  How does ITP affect adults?  How is ITP treated in adults?
  • 99.  What about ITP in pregnant women?  Diagnosing ITP during pregnancy can be difficult, because platelet counts may be low for other reasons. About 5% of women have mildly low platelet counts at the end of a normal pregnancy. The cause of this is unknown. The platelet count goes back to normal right after delivery.  A baby born to a mother with ITP may have a low blood platelet count a few days to a few weeks after birth. These babies are usually kept in the hospital for several days for observation (watching to make sure they are ok) before they go can home.
  • 100.  Thrombotic thrombocytopenic purpura What is thrombotic thrombocytopenic purpura?  Thrombotic thrombocytopenic purpura (TTP) is a rare blood condition characterised by the formation of small clots (thrombi) within the circulation, which results in the consumption of platelets and thus a low platelet count (thrombocytopenia).  What causes TTP?
  • 101.  DRUG-INDUCED IMMUNE THROMBOCYTOPENIA  DRUG-INDUCED IMMUNE THROMBOCYTOPENIA is a condition where the use of certain drugs leads to the formation of antibodies against platelets. These antibodies can cause a low platelet count, which make bleeding more likely. If these antibodies are formed during pregnancy, they may pass from the mother to the fetus.
  • 102.  Thrombocytopenia (nonimmune) drug- induced; Nonimmune  thrombocytopenia - drug-induced  Drug-induced nonimmune thrombocytopenia is a reduction in normally functioning platelets that can be caused by certain drugs.  Platelets are important in forming blood clots. Certain drugs may decrease the number of platelets by damaging the bone marrow where platelets are made. Decreased platelets may cause easy bruising or abnormal bleeding.
  • 103.  PRIMARY THROMBOCYTHEMIA  Essential thrombocythemia; Essential thrombocytosis  Primary thrombocythemia is a condition of overproduction of platelets without a recognizable cause.
  • 104. Causes, incidence, and risk factors  Primary thrombocythemia is a slowly progressing disorder caused by overgrowth of a type of cell that is a precursor of blood cells. Although the platelets are primarily affected, the red blood cells and white blood cells are also involved  The formation of blood clots, called thrombosis, may coincide with bleeding episodes.  It may even cause strokes in some people.  Risk factors are unknown.  The incidence is about 3 out of 100,000 people
  • 105. Symptoms  Nosebleeds (epistaxis )  Bleeding from the gums  Bleeding from the gastrointestinal tract  Easy bruising  Prolonged bleeding from surgical procedures or tooth extraction  Enlarged lymph nodes (rare)  Bloody stools  Headache  Numbness of hands or feet  Dizziness  Ulcers on fingers or toes
  • 106.  Signs and tests  Bone marrow aspiration.  CBC that shows elevated platelet count.  Uric acid level may be elevated.  Physical examination may show enlarged spleen or liver
  • 107. Treatment  If a patient is having life-threatening complications- platelet pheresis.  Long-term decrease of the platelet count using medications can reduce both bleeding and clotting complications.  Most common medications include hydroxyurea, interferon-alpha, or anagrelide. For patients with a known clotting tendency, aspirin may help decrease clotting episodes.  Some patients do not need any treatment.
  • 108. Expectations (prognosis)  The outcome varies with reports ranging from prolonged periods without complications in some people, to fatalities from complications related to hemorrhage and thrombosis in others. Complications  Severe hemorrhage  Thrombotic episodes (stroke, heart attack, or blood clots in extremities)  Acute leukemia or myelofibrosis can develop in some patients
  • 109. HYPERSPLENISM  Hypersplenism is increased activity of the spleen caused by tumors, anemia, malaria, tuberculosis, and various connective tissue and inflammatory diseases.  An enlarged spleen is often accompanied by a low level of one or more types of blood cells. The enlarged spleen can cause stomach pain on the left side, as well as feeling full prematurely after eating
  • 110. DENTAL EVALUATION good thorough medical historygood thorough medical history  a physical examination  screening clinical lab tests  excessive bleeding following surgical procedure  Family HX  Personal HX  Medications  Past & Present Illness  Spontaneous Bleeding
  • 111. REVIEW PATIENT’S MEDS  FIVE DRUGS THAT INTERFERE WITH HEMOSTASIS  ASPIRIN  ANTICOAGULANTS  ANTIBIOTICS  ALCOHOL  ANTICANCER
  • 112. ORAL MANIFESTATIONS  Petechiae & Ecchymosis  Gingival Hyperplasia  Spontaneous Gingival Bleeding  Ulceration of Oral Mucosa  Lymphadenopathy
  • 113. DENTAL PATIENTS  LOW RISK  Patients with No Hx of Bleeding Disorders  Normal Laboratory Results  MODERATE RISK  Patients on Chronic Oral Anticoagulant  Therapy. PT is 1.5 - 2 Times Control Range  Patients on Chronic Aspirin Therapy  HIGH RISK  Patients with Known Bleeding Disorders  Patients without Known Bleeding Disorders Who Have Abnormal Laboratory Results
  • 114. DENTAL MANAGEMENT  LOW RISK PATIENTS  Normal Protocol
  • 115.  MODERATE RISK PATIENTS  Anticoagulants - Consult Physician  Aspirin Therapy - BT, Consult Physician  HIGH RISK PATIENTS  Close Coordination with Physician  Hospitalization (Platelet Transfusion) (Factor Replacement)(Vit K Therapy)(Dialysis
  • 116.  CONCLUSIONS  The history (medical /family history) is extremely important in evaluating patients with disorders of hemostasis.  Dental extractions are a very common major stresses of the haemostatic mechanism, and a prior history of excessive bleeding following an extraction is important.  So, thorough understanding and knowledge about bleeding disorders is very much needed for dental professionals to minimize the complications of many treatment procedures.
  • 117. References  Davidson’s “principles and practice of medicine-19th edition;-Hanslet, Chilvers, Boon, Colledge, Hunters.  Medical emergencies in the dental practice –malammed; 5th edition  Bailey and Love’s Short practice of surgery-23rd edition; Russel, Williams, Bulstrode;  Complications in Oral and Maxillofacial surgery-1st edition; Kaban, Pogrel, Perrot.  Concise Medical Physiology;-5th edition; Chaudhari  Systemic disease in dental treatment-1st edition;- Michael.J.Tullman, Spencer.W.Redding.  Clinical hematology-7th edition;-Maxwell.M.Wintrobe.  www.hemophilia.org  www.google.com

Hinweis der Redaktion

  1. At joints and at injection site